FDA report cites risks of anemia drugs for cancer patients

An FDA staff report raised concerns about risks to cancer patients from anemia drugs such as Amgen's Aranesp and Johnson & Johnson's Procrit. The FDA cited results from five trials showing decreased survival times for patients receiving the drugs, compared with patients getting blood transfusions. An advisory panel is scheduled to meet Thursday to consider stricter labeling for the drugs.

View Full Article in:

Los Angeles Times (tiered subscription model) · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC